Crossmark

Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication

Crossref DOI link: https://doi.org/10.1186/s12885-019-5725-y

Published Online: 2019-06-06

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maynard, Sean K. http://orcid.org/0000-0002-0953-4362
Marshall, Jason D.

MacGill, Randall S.

Yu, Li

Cann, Jennifer A.

Cheng, Lily I.

McCarthy, Michael P.

Cayatte, Corinne

Robbins, Scott H.
Funding

Funding for this research was provided by:

MedImmune LLC
License Information

Text and Data Mining valid from 2019-06-06

Version of Record valid from 2019-06-06
More Information

Article History

Received: 21 November 2018

Accepted: 16 May 2019

First Online: 6 June 2019

Ethics approval and consent to participate

: The study protocols were submitted in writing and approved by the MedImmune Institutional Animal Care and Use Committee (IACUC) in compliance with applicable regulations governing protection of animal in research.

: Not Applicable.

: All authors are current or former employees of MedImmune or AstraZeneca.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below